What is HC Wainwright’s Estimate for TPST Q1 Earnings?

Tempest Therapeutics, Inc. (NASDAQ:TPST) – Equities researchers at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Tempest Therapeutics in a research report issued to clients and investors on Friday, March 28th. HC Wainwright analyst J. Pantginis forecasts that the company will post earnings per share of ($0.34) for the quarter. HC Wainwright currently has a “Buy” rating and a $16.00 target price on the stock. The consensus estimate for Tempest Therapeutics’ current full-year earnings is ($1.39) per share.

Tempest Therapeutics (NASDAQ:TPST) last posted its earnings results on Thursday, March 27th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.07). The business had revenue of $0.49 million for the quarter.

Separately, Scotiabank cut their target price on Tempest Therapeutics from $13.00 to $7.00 and set a “sector outperform” rating on the stock in a report on Friday.

Tempest Therapeutics Trading Down 8.1 %

Tempest Therapeutics stock opened at $0.77 on Monday. Tempest Therapeutics has a 1-year low of $0.70 and a 1-year high of $6.00. The firm’s fifty day simple moving average is $0.87 and its 200-day simple moving average is $0.97. The company has a market capitalization of $33.70 million, a P/E ratio of -0.50 and a beta of -1.83.

Hedge Funds Weigh In On Tempest Therapeutics

A number of institutional investors have recently modified their holdings of TPST. XTX Topco Ltd acquired a new position in Tempest Therapeutics in the 3rd quarter valued at $34,000. Virtu Financial LLC acquired a new stake in shares of Tempest Therapeutics in the fourth quarter valued at about $36,000. Northern Trust Corp increased its stake in shares of Tempest Therapeutics by 233.2% in the fourth quarter. Northern Trust Corp now owns 67,815 shares of the company’s stock worth $57,000 after purchasing an additional 47,461 shares during the period. Millennium Management LLC bought a new position in shares of Tempest Therapeutics in the fourth quarter worth about $158,000. Finally, Geode Capital Management LLC lifted its position in shares of Tempest Therapeutics by 61.0% during the 4th quarter. Geode Capital Management LLC now owns 354,276 shares of the company’s stock worth $296,000 after purchasing an additional 134,209 shares during the last quarter. Institutional investors own 22.52% of the company’s stock.

About Tempest Therapeutics

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.